Rhinovirus type 15 passaged three times in WI-38 cells produced illness in only one of 35 volunteers, but infection resulted in formation of significant quantities of antibodies in the serums of 100%, and in nasal secretions of 89%, of infected volunteers. The inoculum contained large-(60%) and small-(40%) plaque variants. "Purified" large-and small-plaque inocula were prepared, and each was administered to 20 volunteers. There was a significant association of illness with the small-plaque inocula (P < 0.01) but the incidence of infection, quantitative virus shedding patterns, and mean serum and nasal secretory antibodies were not significantly different between the two groups. These findings suggest that plaque size may be an in vitro marker of attenuation of illness production by rhinoviruses.
Rhinoviruses are the most frequently isolated viruses from adults with common colds (9) . Attempts to develop conventional parenteral vaccines as a means for control of these illnesses have not been successful, since such vaccines have been poorly antigenic or have failed to induce significant protection against infection (6, 10) . Therefore, other methods for control of these infections are needed.
We recently reported attenuation of illness in humans with rhinovirus type 15 passaged three times in tissue cultures (5) . In the present studies, this work was extended to 35 additional volunteers, and serial determination of serum and nasal secretion antibody was performed. Attenuation of illness was confirmed, and development of antibody in both locations resulted from this infection. Studies of plaque size revealed that the third-passage inoculum contained predominantly large-plaque-producing variants. "Purified" large-and small-plaque inocula were then made and administered to volunteers. Illness developed more frequently in volunteers given the small-plaque variant, suggesting that in vitro markers of attenuation may be found which could lead to selection of attenuated rhinovirus variants for vaccine development. MATERIALS acquiring volunteers and performing studies in the institution are essentially the same as those previously reported (3, 8) .
Clinical evaluation. Volunteers were examined once daily for 10 days by physicians who knew the date of inoculation but not the nature of the virus inoculum. Oral temperatures were recorded every 12 h. A designation of respiratory illness was based on daily evaluations and graded according to severity (1+, 2+, or 3+), predominant site of involvement (rhinitis, pharyngitis, tracheobronchitis, or systemic illness), and occurrence of fever (>38 C).
Virus inocula. The challenge stock of rhinovirus type 15 WI3 was prepared from third-passage harvests in human embryonic lung fibroblast (WI-38) tissue cultures and safety tested as previously described (1 and 0.36 mmol of MgCl2 per ml. Flasks were incubated at 33 C in 5% CO2 for 5 or 9 days. Fluid neutral red (1: 1,000) was overlaid, and plaques were examined 18 to 24 h later. Small plaques were 2 to 3 mm at 6 days and 6 to 10 mm at 10 days. Large plaques were 5 to 7 mm at 6 days and 12 to 17 mm at 10 days.
RESULTS
Responses of volunteers to nasal inoculations with rhinovirus type 15 WI3. Rhinovirus type 15 WI3 was administered to 35 volunteers with low or undetectable levels of serum antibody ( < 1: 4). The inoculum dose was 320 TCID50, approximately 200 HID5O. Twentyseven volunteers shed the inoculated virus type, and the mean number of isolates per man was 4.8. All of these volunteers, and four others who did not shed virus, developed fourfold or greater serum neutralizing antibody responses, making a total of 31 of 35 infected volunteers (89%). Of the four volunteers who resisted challenge, none had detectable neutralizing antibody in nasal secretions, and only one had serum antibody (1:4).
The illness results are shown in Table 1 and are compared with previous results with secondpassage material (WI2) (4) . Although these studies were not performed simultaneously, the continued ability of the second-passage inoculum to produce illness has been demonstrated.
Only one of 31 volunteers who received WI3 developed illness, and the illness was accompanied by fever (38 C). His specimens were also tested in human embryonic kidney and rhesus monkey kidney cultures and, after neutraliza- (Table 2) .
Volunteer inocula containing predominantly small-and large-plaque variants were prepared from the WI3 stock as described in Materials (Table 3) . In each case, titration revealed that the dose administered was large and was somewhat larger for the LP than the SP pool. Although infection rates were similar for the two pools, illness rates were significantly different. However, among ill volunteers, illness caused by the two inocula was indistinguishable in terms of severity, incidence of fever, and duration.
All volunteers in the WI1 -LP group began to shed virus on the first or second day after inoculation, whereas five volunteers in the WI11-SP group had onsets on the third day or later (P < 0.10, > 0.05). Quantitative virus shedding patterns for the two inoculum groups are shown in Fig. 2 . Although the WI 1-LP group consistently shed more detectable virus, these differences also are not significant (P > 0.05, t test). Comparison of mean peak quantities detected (2.77 versus 2.30 log10 TCID50) and median duration of shedding (7.5 versus 7.5 days) also failed to reveal significant differences between the two groups (P > 0.10, t test).
Antibody responses of the two groups were similar. The frequency of development of significant serum and nasal secretion antibody re- strain after three passages in human embryonic lung fibroblast tissue cultures. In a previous report, none of eight volunteers who were infected with type 15 WI3 became ill. If these results are combined with those of the present report, illness has been observed in only one of 39 (2.6%) of volunteers who became infected with this inoculum. This finding is in striking contrast to the 75% illness rate observed with the type 15 WI2 inoculum. The 75% rate is similar to that we have observed with types 13, 15, 17, and that reported in naturally occurring infections (9) . In addition to attenuation of illness production, it has been shown that type 15 WI3 inoculum was 50-fold less infectious for man (5).
The alternative possibility, that the WI, inoculum is more infectious for tissue cultures, seems unlikely since the WI2 and WI3 stocks exhibited similar titers in WI-38 culture ( discussed previously, it may be that the volunteer inoculum was not 100% purified. This is suggested by the predominance of small-plaque variants detected in nasal wash specimens from volunteers infected with the WI1 -LP inoculum, although this finding may be partially explained by phenotypic variation. Moreover, calculations using distribution of plaque size for the WI3 and W11,-LP pools and doses administered indicate that volunteers given the WI,,-LP pool received about eight times as much small-plaque virus as did those given the WIs pool. Thus, the opportunity for infection with illness-producing virus was greater. If this is the correct explanation, it would imply a growth advantage for the small-plaque variant in man and the large-plaque variant in tissue cultures, a finding supported by the uniformly greater recovery of SP as compared to LP from volunteers. A third possibility, also compatible with the plaque distribution of virus in nasal wash specimens, is that the large-plaque variant may be genetically unstable so that reversion to small plaque occurs with human passage. Finally, it may be that plaque size variation and attenuation are not interdependent properties.
In any event, the findings presented suggest that plaque size may be an in vitro marker of attenuation of illness production by rhinoviruses. Thus, it might be possible to select large-plaque variants of other rhinovirus types which would be potential live virus vaccine candidates.
